دورية أكاديمية
Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
| العنوان: | Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis. |
|---|---|
| المؤلفون: | Stone GW; The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: gregg.stone@mountsinai.org., Christiansen EH; Aarhus University Hospital, Aarhus, Denmark., Ali ZA; St Francis Hospital, Roslyn, NY, USA., Andreasen LN; Aarhus University Hospital, Aarhus, Denmark., Maehara A; Cardiovascular Research Foundation, New York, NY, USA; Columbia University Medical Center, New York, NY, USA., Ahmad Y; Yale School of Medicine, Yale University, New Haven, CT, USA., Landmesser U; Deutsches Herzzentrum Charité, Charité Universitätsmedizin Berlin, Berlin, Germany; German Center for Cardiovascular Research (DZHK), Berlin, Germany., Holm NR; Aarhus University Hospital, Aarhus, Denmark. |
| المصدر: | Lancet (London, England) [Lancet] 2024 Mar 02; Vol. 403 (10429), pp. 824-837. Date of Electronic Publication: 2024 Feb 21. |
| نوع المنشور: | Journal Article; Meta-Analysis; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2004- : London : Elsevier Original Publication: London : J. Onwhyn |
| مواضيع طبية MeSH: | Drug-Eluting Stents* , Erythema Multiforme* , Myocardial Infarction* , Percutaneous Coronary Intervention* , Thrombosis*, Humans ; Angiography ; Network Meta-Analysis ; Randomized Controlled Trials as Topic |
| مستخلص: | Background: Previous meta-analyses have shown reduced risks of composite adverse events with intravascular imaging-guided percutaneous coronary intervention (PCI) compared with angiography guidance alone. However, these studies have been insufficiently powered to show whether all-cause death or all myocardial infarction are reduced with intravascular imaging guidance, and most previous intravascular imaging studies were done with intravascular ultrasound rather than optical coherence tomography (OCT), a newer imaging modality. We aimed to assess the comparative performance of intravascular imaging-guided PCI and angiography-guided PCI with drug-eluting stents. Methods: For this systematic review and updated meta-analysis, we searched the MEDLINE, Embase, and Cochrane databases from inception to Aug 30, 2023, for studies that randomly assigned patients undergoing PCI with drug-eluting stents either to intravascular ultrasound or OCT, or both, or to angiography alone to guide the intervention. The searches were done and study-level data were extracted independently by two investigators. The primary endpoint was target lesion failure, defined as the composite of cardiac death, target vessel-myocardial infarction (TV-MI), or target lesion revascularisation, assessed in patients randomly assigned to intravascular imaging guidance (intravascular ultrasound or OCT) versus angiography guidance. We did a standard frequentist meta-analysis to generate direct data, and a network meta-analysis to generate indirect data and overall treatment effects. Outcomes were expressed as relative risks (RRs) with 95% CIs at the longest reported follow-up duration. This study was registered with the international prospective register of systematic reviews (PROSPERO, number CRD42023455662). Findings: 22 trials were identified in which 15 964 patients were randomised and followed for a weighted mean duration of 24·7 months (longest duration of follow-up in each study ranging from 6 to 60 months). Compared with angiography-guided PCI, intravascular imaging-guided PCI resulted in a decreased risk of target lesion failure (RR 0·71 [95% CI 0·63-0·80]; p<0·0001), driven by reductions in the risks of cardiac death (RR 0·55 [95% CI 0·41-0·75]; p=0·0001), TV-MI (RR 0·82 [95% CI 0·68-0·98]; p=0·030), and target lesion revascularisation (RR 0·72 [95% CI 0·60-0·86]; p=0·0002). Intravascular imaging guidance also reduced the risks of stent thrombosis (RR 0·52 [95% CI 0·34-0·81]; p=0·0036), all myocardial infarction (RR 0·83 [95% CI 0·71-0·99]; p=0·033), and all-cause death (RR 0·75 [95% CI 0·60-0·93]; p=0·0091). Outcomes were similar for OCT-guided and intravascular ultrasound-guided PCI. Interpretation: Compared with angiography guidance, intravascular imaging guidance of coronary stent implantation with OCT or intravascular ultrasound enhances both the safety and effectiveness of PCI, reducing the risks of death, myocardial infarction, repeat revascularisation, and stent thrombosis. Funding: Abbott. Competing Interests: Declaration of interests GWS has received speaker honoraria from Medtronic, Pulnovo, Infraredx, Abiomed, Amgen, and Boehringer Ingelheim; has served as a consultant to Abbott, Daiichi Sankyo, Ablative Solutions, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Robocath, Miracor, Vectorious, Abiomed, Valfix, TherOx, HeartFlow, Neovasc, Ancora, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical, Millennia Biopharma, Oxitope, Cardiac Success, and HighLife; and has equity or options from Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and Xenter. GWS's employer, Mount Sinai Hospital, receives research grants from Abbott, Abiomed, Bioventrix, Cardiovascular Systems, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo, and V-wave. EHC has received speaker honoraria from Abbott and receives research grants from Abbott, Asahi Intecc, Biosensors, Biotronik, Boston Scientific, OrbusNeich, and Philips. ZAA reports institutional grant support from Abbott, Abiomed, Acist Medical, Boston Scientific, Cardiovascular Systems, Medtronic, the National Institute of Health, Opsens Medical, Philips, and Teleflex; consulting fees from AstraZeneca, Philips, and Shockwave; and equity in Elucid, Spectrawave, Shockwave, and VitalConnect. AM has received speaker honoraria from Nipro and is a consultant for Boston Scientific. YA is a consultant for Cardiovascular Systems and Shockwave, and serves on the Medical Advisory Board of Boston Scientific. UL has received speaker or advisory honoraria from Abbott, Boston Scientific, Amgen, Bayer, NovoNordisc, Pfizer, and Sanofi. NRH has received institutional research grants from Abbott, Biosensors, Boston Scientific, Medis Medical Imaging, and Reva Medical, and speaker fees from Abbott, Cardirad, and Terumo. LNA declares no competing interests. (Copyright © 2024 Elsevier Ltd. All rights reserved.) |
| تواريخ الأحداث: | Date Created: 20240224 Date Completed: 20240304 Latest Revision: 20240307 |
| رمز التحديث: | 20240308 |
| DOI: | 10.1016/S0140-6736(23)02454-6 |
| PMID: | 38401549 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1474-547X |
|---|---|
| DOI: | 10.1016/S0140-6736(23)02454-6 |